Read what hematology experts are saying about ASH this year:
ASH: Seeking the Higher-Hanging Fruit
By John Gever, Senior Editor, MedPage TODAY
December 7th, 2012
ATLANTA — New therapies for “hard-to-heal” hematologic disorders and strategies for reducing treatment-related toxicities without sacrificing efficacy will be major themes at the American Society of Hematology’s annual meeting, top officials said.
Also featured at the meeting, which runs here through Tuesday, will be important news on the role of genomics in managing patients with blood-related illnesses, said ASH President Armand Keating, MD, of the University of Toronto, and Secretary Charles Abrams, MD, of the University of Pennsylvania in Philadelphia.
Keating said meeting attendees could look forward to “new solutions for targeted therapies that will overcome some of the current limitations that we have” as well as “doing more with less” — that is, achieving positive outcomes with smaller drug doses…
There is a lot of information here. I found it interesting, but most isn’t about multiple myeloma. The article did mention three important studies that do involve myeloma and stem cell transplantation:
- A large, multicenter study of pomalidomide and dexamethasone as second-line therapy for multiple myeloma
- An early-stage trial of an oral proteasome inhibitor, MLN9708, in multiple myeloma
- A study of the cancer drug vorinostat (Zolinza) as prophylaxis against graft-versus-host disease following allogeneic stem cell transplantation
You can read the entire MedPage TODAY article by CLICKING HERE.
Feel good and keep smiling! Pat
Hiç yorum yok:
Yorum Gönder